Shenogen’s Icaritin: A New First-Line Therapy For HCC?

Preliminary data from a Phase II study has unveiled promising results for Shenogen’s icaritin, a plant-derived product being studied as a possible therapy for hepatocellular carcinoma. The drug’s safety profile makes it particularly appealing, says the Chinese startup’s chief business officer.